Insulin Degludec; Liraglutide Patents

Given below is the list of patents protecting Insulin Degludec; Liraglutide, along with the drug name that holds that patent and the company name owning that drug.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Insulin Degludec; Liraglutide's patents.

Latest Legal Activities on Insulin Degludec; Liraglutide's Patents

Given below is the list recent legal activities going on the following patents of Insulin Degludec; Liraglutide.

Activity	Date	Patent Number
Today's Critical Events
Payment of Maintenance Fee, 8th Year, Large Entity	17 Feb, 2022	US8846618
Payment of Maintenance Fee, 12th Year, Large Entity	21 Apr, 2021	US7615532
Payment of Maintenance Fee, 12th Year, Large Entity	18 Oct, 2018	US7235627
Patent Term Extension Certificate Critical	11 Sep, 2018	US7615532
Payment of Maintenance Fee, 4th Year, Large Entity	22 Mar, 2018	US8846618
Notice of Final Determination -Eligible	14 Mar, 2018	US7615532
FDA Final Eligibility Letter Critical	20 Sep, 2017	US7615532
PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED Critical	18 Apr, 2017	US7615532
Terminal Disclaimer Filed Critical	14 Apr, 2017	US7615532
Resp. to req. for info. sent under 37 CFR 1.750	13 Apr, 2017	US7615532

Insulin Degludec; Liraglutide's Family Patents

Full family tree

Explore Our Curated Drug Screens